English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Tuesday, June 27, 2023
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, Its Innovative Drug Anaprozole Sodium Enteric-coated Tablets Obtains Drug Registration Approval From NMPA
Monday, June 19, 2023
四环医药及轩竹生物齐入围《2023中国药品研发综合实力排行榜 TOP100》
四環醫藥及軒竹生物齊入圍《2023中國藥品研發綜合實力排行榜 TOP100》
Thursday, June 8, 2023
Xuanzhu Biopharm, a subsidiary of Sihuan Pharmaceutical, progresses at full speed in innovative research and development, Presents major research results of birociclib, the start product, at the international stage in ASCO
四环医药旗下轩竹生物创新研发全速前进 携明星产品吡罗西尼重磅研究成果登国际舞台于ASCO亮相
四環醫藥旗下軒竹生物創新研發全速前進 攜明星產品吡羅西尼重磅研究成果登國際舞台於ASCO亮相
Friday, March 24, 2023
四环医药(0460.HK)发布2022年全年业绩
四環醫藥(0460.HK)發佈2022年全年業績
Sihuan Pharmaceutical (0460.HK) Announces 2022 Annual Results
Wednesday, January 4, 2023
四环医药(0460.HK):惠升生物成功完成A +轮融资,加速糖尿病及并发症领域布局

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575